Melpida - Elpida Therapeutics
Latest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Elpida Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Paraplegia
Most Recent Events
- 18 Nov 2024 Elpida Therapeutics plans a phase III trial for Paraplegia in an undisclosed location (intrathecal) (NCT06692712)